Tekla Capital Management LLC Buys Pfizer Inc, Johnson & Johnson, Esperion Therapeutics Inc, Sells Alexion Pharmaceuticals Inc, Biomarin Pharmaceutical Inc, Shire PLC

• New Purchases: ESPR, NKTR, MDCO, BPMC, CRSP, FGEN, EDIT, ALBO, BHVN, BDX,
• Added Positions: PFE, JNJ, BMY, ANTM, ABBV, UNH, GWPH, SAGE, LLY, AGN,
• Reduced Positions: GILD, AMGN, BIIB, ALXN, BMRN, CELG, SHPG, REGN, NVRO, TEVA,
• Sold Out: NUVA, DXCM, AGNPA.PFD, CASC, ADVM, BCRX, IPXL, KPTI, ZFGN,

For the details of Tekla Capital Management LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Tekla+Capital+Management+LLC

1. Gilead Sciences Inc (GILD) - 2,063,699 shares, 6.08% of the total portfolio. Shares reduced by 18.12%
2. Celgene Corp (CELG) - 1,352,842 shares, 4.72% of the total portfolio. Shares reduced by 10.64%
3. Amgen Inc (AMGN) - 700,588 shares, 4.67% of the total portfolio. Shares reduced by 18.74%
4. Johnson & Johnson (JNJ) - 893,082 shares, 4.47% of the total portfolio. Shares added by 21.32%
5. Biogen Inc (BIIB) - 378,703 shares, 4.05% of the total portfolio. Shares reduced by 15.01%

Tekla Capital Management LLC initiated holding in Esperion Therapeutics Inc. The purchase prices were between $65.94 and $80.76, with an estimated average price of $73.43. The stock is now traded at around $40.59. The impact to a portfolio due to this purchase was 0.54%. The holding were 189,287 shares as of 2018-03-31.

Tekla Capital Management LLC initiated holding in Nektar Therapeutics Inc. The purchase prices were between $57.4 and $108.44, with an estimated average price of $85.89. The stock is now traded at around $80.68. The impact to a portfolio due to this purchase was 0.52%. The holding were 124,517 shares as of 2018-03-31.

Tekla Capital Management LLC initiated holding in The Medicines Co. The purchase prices were between $24.83 and $35.48, with an estimated average price of $31.25. The stock is now traded at around $30.77. The impact to a portfolio due to this purchase was 0.36%. The holding were 278,391 shares as of 2018-03-31.

Tekla Capital Management LLC initiated holding in Blueprint Medicines Corp. The purchase prices were between $73.28 and $102.95, with an estimated average price of $85.85. The stock is now traded at around $80.74. The impact to a portfolio due to this purchase was 0.27%. The holding were 74,221 shares as of 2018-03-31.

Tekla Capital Management LLC initiated holding in CRISPR Therapeutics AG. The purchase prices were between $23.48 and $58.17, with an estimated average price of $40.78. The stock is now traded at around $54.80. The impact to a portfolio due to this purchase was 0.25%. The holding were 141,191 shares as of 2018-03-31.

Tekla Capital Management LLC initiated holding in FibroGen Inc. The purchase prices were between $45.35 and $61.65, with an estimated average price of $52.6. The stock is now traded at around $48.65. The impact to a portfolio due to this purchase was 0.19%. The holding were 104,307 shares as of 2018-03-31.

Tekla Capital Management LLC added to a holding in Pfizer Inc by 110.44%. The purchase prices were between $33.63 and $39.02, with an estimated average price of $36.23. The stock is now traded at around $35.79. The impact to a portfolio due to this purchase was 1.5%. The holding were 2,051,943 shares as of 2018-03-31.

Tekla Capital Management LLC added to a holding in Johnson & Johnson by 21.32%. The purchase prices were between $125.1 and $148.14, with an estimated average price of $135.16. The stock is now traded at around $127.17. The impact to a portfolio due to this purchase was 0.79%. The holding were 893,082 shares as of 2018-03-31.

Tekla Capital Management LLC added to a holding in Bristol-Myers Squibb Company by 50.58%. The purchase prices were between $59.92 and $68.98, with an estimated average price of $64.33. The stock is now traded at around $51.99. The impact to a portfolio due to this purchase was 0.44%. The holding were 525,722 shares as of 2018-03-31.

Tekla Capital Management LLC added to a holding in Anthem Inc by 103.66%. The purchase prices were between $215.63 and $258.19, with an estimated average price of $234.91. The stock is now traded at around $231.36. The impact to a portfolio due to this purchase was 0.4%. The holding were 91,482 shares as of 2018-03-31.

Tekla Capital Management LLC added to a holding in AbbVie Inc by 30.15%. The purchase prices were between $92.01 and $123.21, with an estimated average price of $109.85. The stock is now traded at around $105.65. The impact to a portfolio due to this purchase was 0.39%. The holding were 450,738 shares as of 2018-03-31.

Tekla Capital Management LLC added to a holding in GW Pharmaceuticals PLC by 343.14%. The purchase prices were between $110.14 and $139.71, with an estimated average price of $125.74. The stock is now traded at around $143.58. The impact to a portfolio due to this purchase was 0.38%. The holding were 110,784 shares as of 2018-03-31.

Tekla Capital Management LLC sold out a holding in NuVasive Inc. The sale prices were between $46.03 and $61.28, with an estimated average price of $50.71.

Tekla Capital Management LLC sold out a holding in DexCom Inc. The sale prices were between $52.25 and $74.16, with an estimated average price of $59.15.

Tekla Capital Management LLC sold out a holding in Cascadian Therapeutics Inc. The sale prices were between $3.56 and $10.06, with an estimated average price of $7.81.

Tekla Capital Management LLC sold out a holding in Allergan PLC. The sale prices were between $543.5 and $674.47, with an estimated average price of $612.79.

Tekla Capital Management LLC sold out a holding in Adverum Biotechnologies Inc. The sale prices were between $3.5 and $7.95, with an estimated average price of $6.15.

Tekla Capital Management LLC sold out a holding in Biocryst Pharmaceuticals Inc. The sale prices were between $4.35 and $5.82, with an estimated average price of $5.14.